About Zipalertinib

Cullinan Oncology and Taiho Pharmaceutical Co., Ltd., are developing zipalertinib for non–small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) exon 20 insertion (EGFRex20ins) mutation.

CLN-081 is an orally available, differentiated, irreversible EGFR inhibitor that, based on preclinical data, selectively targets cells expressing EGFRex20ins mutations while sparing cells expressing wild type EGFR.

ZIPALERTINIB: UNIQUE DESIGN PROPERTIES



- Distinct chemical scaffold
- *HER2*-sparing
- High selectivity to mutant vs WT EGFR

In the U.S., approximately 16% of NSCLC cases harbor EGFR mutations, with insertions at exon 20 accounting for 12% of those mutations. Patients with EGFRex20ins are known to have poorer outcomes than those with more common EGFR mutations, such as exon 19 deletion.[1]

While there are approved therapies for the treatment of patients with EGFRex20ins, approved EGFR inhibitors do not adequately address the needs of this patient population.

CLINICAL DATA

Based on the response rate and safety and tolerability profile shown to date, zipalertinib has the potential to be a treatment option for patients with EGFRex20ins.[2]

Data on zipalertinib presented in an oral presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting highlighted the potential of zipalertinib in patients with heavily pretreated advanced EGFRex20ins mutations with NSCLC.

DATA FROM ONGOING PHASE 1 / 2A STUDY (100mg BID)

41%
confirmed overall rate of response (16/39)

12-month
median progression-free survival

5%
rate of grade >=3 adverse events 5% rate of discontinuation

CULLINAN AND TAIHO PARTNERSHIP

Taiho Pharmaceutical Co., Ltd., discovered zipalertinib in 2019, prior to licensing the molecule to a subsidiary of Cullinan Oncology, Inc. in February 2019. In May 2022, Cullinan Oncology and Taiho entered into a co-development and co-commercialization agreement. The partnership is suited to bring zipalertinib to patients and leverages Taiho's intimate knowledge of the compound while providing additional financial resources that allow Cullinan to advance development of a diverse pipeline of oncology assets for patients with cancer.

TIMELINE OF ZIPALERTINIB



CURRENT PUBLICATIONS

- Poster – Abstract 9007: Phase1/2a Study of CLN-081 in NSCLC Patients with EGFR Exon 20 Insertion (ex20ins) Mutations (ASCO 2022)
- Poster – Abstract 9077: Safety and Activity of CLN-081 (TAS6417) in NSCLC With EGFR Exon 20 Insertion Mutations (Ins20) (ASCO 2021)
- Poster – Preliminary Safety and Activity of CLN-081 in NSCLC With EGFR Exon 20 Insertion Mutations (Ins20) (ESMO 2020)
- Poster – Multicenter Phase 1/2a Trial of CLN-081 (TAS6417) in NSCLC Patients With EGFR Exon 20 Insertion Mutations (WCLC 2019)

REFERENCES

1. Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. *PLOS ONE*. 2021;16(3). doi:10.1371/journal.pone.0247620
2. Cullinan Oncology announces clinical and regulatory update for CLN-081 in NSCLC EGFR exon 20 patients. Cullinan Oncology, Inc. Accessed April 19, 2022. https://investors.cullinanoncology.com/news-releases/news-release-details/cullinan-oncology-announces-clinical-and-regulatory-update-cln

cullinan ONCOLOGY